
Liso-Cel Combo Shows Deep, Durable Responses in Relapsed/Refractory CLL/SLL
In the phase 1/2 TRANSCEND CLL 004 trial, liso-cel plus ibrutinib produced a 45% CR/CRi rate in a heavily pretreated relapsed/refractory CLL/SLL population.
The combination of lisocabtagene maraleucel (liso-cel; Breyanzi) and ibrutinib (Imbruvica) produced deep and durable responses with a manageable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to primary results from the ibrutinib-combination cohort of the
Among 51 patients who received liso-cel at the recommended dose level, the investigator-assessed complete response/complete response with incomplete marrow recovery (CR/CRi) rate was 45% (95% CI, 31%-60%), and the overall response rate (ORR) was 86% (95% CI, 74%-94%). Undetectable minimal residual disease at a sensitivity of 10⁻⁴ (uMRD4) was achieved in 86% (95% CI, 74%-94%) of patients in peripheral blood and 84% (95% CI, 71%-93%) in bone marrow.
The median duration of response (DOR) was 41.4 months (95% CI, 23.3-not reached [NR]), and the median progression-free survival (PFS) was 31.4 months (95% CI, 20.1-NR), with a 24-month rate of 62% (95% CI, 46%-74%). The median overall survival (OS) was NR (95% CI, 27.5-NR), with a 24-month rate of 79.5% (95% CI, 65%-88%).
Across all 56 patients treated with the combination, grade 3 or higher treatment-emergent adverse events (TEAEs) occurred in 86%, most commonly neutropenia (52%) and anemia (41%); no grade 5 TEAEs were reported. Cytokine release syndrome (CRS) occurred in 80% of patients, including grade 3 events in 4% and no grade 4 or 5 events. Neurological events (NEs) occurred in 41%, with grade 3 events in 9%, a grade 4 event in 2%, and no grade 5 events. Grade 3 or higher ibrutinib-related TEAEs occurred in 43%, including hypertension (7%) and atrial fibrillation (2%). Second primary malignancies occurred in 9% of patients, none of which were T-cell malignancies.
“Liso-cel plus ibrutinib treatment demonstrated substantial efficacy, with deep remissions in patients with [relapsed/refractory] CLL/SLL. The safety profile was manageable, with low rates of severe CRS and NEs and no new safety signals or added toxicity, supporting the potential of the combination in this population,” lead author William G. Wierda, MD, PhD, professor of medicine and section chief of CLL in the department of Leukemia at The University of Texas MD Anderson Cancer Center, wrote in the publication with study coinvestigators.1
TRANSCEND CLL 004 is a multicenter, open-label, phase 1/2 study conducted in the US. In the combination cohort, patients started or continued ibrutinib at 420 mg daily at enrollment and through 90 days after liso-cel infusion, or longer per investigator discretion. After lymphodepleting chemotherapy with fludarabine and cyclophosphamide, patients received liso-cel at 50 × 10⁶ (dose level 1; n = 5) or 100 × 10⁶ (dose level 2; n = 51) chimeric antigen receptor (CAR)–positive T cells; dose level 2 was selected for expansion. The 56 treated patients had a median of 5 prior lines of therapy (range, 1-13); 98% had high-risk cytogenetics, all had received a prior Bruton tyrosine kinase (BTK) inhibitor, and 55% had experienced BTK inhibitor progression and venetoclax (Venclexta) failure. The median follow-up was 24.8 months.
The primary end point of the dose-expansion portion was investigator-assessed CR/CRi rate at the recommended dose. Secondary end points included safety, ORR, uMRD4 rate, DOR, time to response, PFS, and OS.
In exploratory analyses, CAR-positive T cells from patients treated with the combination showed a significantly lower T-cell exhaustion gene signature score at peak expansion than those from patients treated with liso-cel monotherapy, and a lower exhaustion score was associated with improved PFS (P = 0.01).
The investigators noted that results compared favorably with the trial’s liso-cel monotherapy cohort, which reported a CR/CRi rate of 18% and an ORR of 43% in patients with prior BTK inhibitor progression and venetoclax failure. In post hoc propensity score analyses, the combination was associated with significantly higher CR/CRi rates and ORR, with no differences in PFS or OS. However, the cohort was nonrandomized and not powered for hypothesis testing, cross-cohort comparisons should be made with caution, and variability in ibrutinib duration after infusion limits conclusions about the optimal length of ibrutinib therapy.
Liso-cel is currently approved by the FDA under accelerated approval for adults with relapsed/refractory CLL or SLL who have received at least 2 prior lines of therapy, including a BTK inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor; the label does not include combination use with ibrutinib.2
References
- Wierda WG, Dorritie K, Gauthier J, et al. Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004. Blood. 2026;148(20):2462-2475. doi:10.1182/blood.2026033565
- Breyanzi. Prescribing information. Juno Therapeutics, Inc, a Bristol Myers Squibb Company; 2026. Accessed November 18, 2026. https://tinyurl.com/dtebbw2a
Related to this article







